Description
Clinical Description
Lenisna 200 (1 × 200mg) is a poly-D,L-lactic acid (PDLLA)-based injectable biostimulator designed for professional aesthetic use. Unlike traditional hyaluronic acid dermal fillers that primarily provide immediate volumising effects through gel implantation, Lenisna PLA works by stimulating a biological response within the skin tissue, supporting collagen production over time.
The product combines PDLLA microspheres with hyaluronic acid (HA) to provide a dual-action approach: immediate hydration and skin conditioning from HA, alongside gradual collagen stimulation associated with the PDLLA component.
Lenisna is intended for use by qualified healthcare professionals in aesthetic medicine procedures where improvement of skin quality, elasticity, and tissue appearance is required. The product belongs to the category of collagen-stimulating injectables and is commonly grouped with other biostimulatory treatments such as PLLA and PDLLA-based products.
The exact PDLLA concentration, HA concentration, and formulation specifications should be confirmed from the manufacturer’s official technical documentation or IFU.
What Lenisna 200 Is Similar To
Lenisna belongs to the category of collagen-stimulating injectable treatments, making it comparable in concept to products such as Profhilo and other PLLA or PDLLA-based biostimulators.
Unlike Profhilo®, which is a high-concentration hyaluronic acid injectable primarily designed for bio-remodelling and hydration effects, Lenisna uses PDLLA microspheres combined with HA to encourage a longer biological response associated with collagen stimulation.
Lenisna may also be compared with PLLA-based products such as Sculptra, although the polymer type, formulation characteristics, approved indications, and clinical protocols differ between products.
The key distinction between collagen stimulators and traditional dermal fillers is that biostimulators are designed to encourage gradual tissue changes rather than provide only direct gel-based augmentation.
This comparison is provided for clinical orientation only and does not imply interchangeability.
Treatment Areas / Indications
According to available product information, Lenisna is intended for professional aesthetic applications involving improvement of skin appearance and tissue quality.
Treatment areas reported in publicly available product descriptions include:
- Facial skin rejuvenation areas
- Areas requiring improvement in skin elasticity and firmness
- Tissue quality enhancement procedures
Specific anatomical treatment areas, approved indications, and injection sites should be confirmed according to the official manufacturer IFU.
Usage / Administration (IFU-Only Section)
Lenisna should only be administered by qualified medical professionals with appropriate training in injectable aesthetic procedures.
Administration should be performed under appropriate aseptic conditions and according to professional medical-device standards.
Some aesthetic practitioners describe specific dilution methods, injection patterns, or treatment protocols for PDLLA-based products; however, these approaches should not be considered official manufacturer guidance unless specifically included within the Lenisna IFU.
Ingredient List
The main components associated with Lenisna PLA include:
- Poly-D,L-lactic acid (PDLLA) microspheres – biodegradable polymer component associated with collagen stimulation
- Hyaluronic acid (HA) – included as part of the formulation to support hydration and product characteristics
Presentation & Longevity
Presentation
Lenisna 200 is supplied as:
- 1 × 200mg vial
The product presentation should be verified against the manufacturer packaging and current distributor documentation.
Longevity
As a collagen-stimulating injectable, Lenisna is designed to produce gradual biological effects rather than only immediate correction.
The exact duration of clinical results depends on multiple factors including:
- patient characteristics,
- treatment area,
- injection protocol,
- individual collagen response.
Safety Notes / Contraindications
Lenisna 200 (1 × 200mg) is an injectable medical aesthetic device intended for administration by appropriately trained healthcare professionals only. As with other injectable aesthetic products, treatment should be performed following appropriate patient assessment, sterile technique, and manufacturer instructions.
Potential contraindications and precautions include:
- Known hypersensitivity or allergy to any component of the product.
- Active infection, inflammation, or skin disease at or near the intended injection area.
- Patients with conditions or circumstances where injectable aesthetic procedures are considered unsuitable should be carefully assessed before treatment.
- The product should not be used outside the indications and administration guidelines provided by the manufacturer.
Possible injection-related reactions associated with injectable aesthetic procedures may include temporary redness, swelling, tenderness, bruising, or discomfort at the treatment site.
Patients should be informed that individual responses vary and outcomes depend on factors including skin condition, treatment area, practitioner technique, and biological response.
Regulatory Status
Lenisna is marketed as a professional injectable aesthetic medical device manufactured by VAIM Co., Ltd.
Available product documentation indicates:
- Product category: Injectable collagen-stimulating implant / PDLLA-based aesthetic device
- Presentation: 1 × 200mg vial
- Manufacturer: VAIM Co., Ltd.
- CE marking: Reported by professional distributors; regulatory documentation should be verified against the current product packaging and official technical file.
Regulatory classification:
Regulatory details should always be confirmed through the current manufacturer IFU, product label, and applicable medical-device databases for the intended market.
FAQ
1. What is Lenisna 200 (1 × 200mg) and how does it work?
Lenisna 200 is a PDLLA-based injectable biostimulator designed to support collagen stimulation and improve tissue quality. The formulation combines poly-D,L-lactic acid (PDLLA) with hyaluronic acid (HA), creating a hybrid approach that differs from traditional HA-only fillers. The HA component provides formulation characteristics and hydration support, while PDLLA particles are designed to encourage a gradual biological response associated with collagen production.
2. Is Lenisna a dermal filler or a skin booster?
Lenisna is generally classified as a collagen-stimulating injectable rather than a conventional HA dermal filler. Traditional dermal fillers primarily rely on cross-linked hyaluronic acid gels to provide structural volume, while Lenisna uses PDLLA technology intended to stimulate collagen formation over time.
Because of this mechanism, Lenisna is often grouped with biostimulatory injectables alongside other collagen-supporting treatments. However, product indications and clinical use should always follow the manufacturer’s official documentation.
3. How long do results from Lenisna last?
The duration of visible results with Lenisna depends on multiple factors, including individual collagen response, treatment area, product application, and patient characteristics.
Some professional product descriptions report results lasting approximately 18–24 months; however, longevity can vary between patients and should not be considered guaranteed. The exact duration should be interpreted according to manufacturer-supported clinical information and practitioner assessment.
4. What is the difference between Lenisna and Profhilo®?
Lenisna and Profhilo® belong to different categories of injectable aesthetic treatments.
Profhilo® is a hyaluronic acid-based injectable designed around high-concentration HA technology and skin bio-remodelling concepts. Lenisna combines PDLLA particles with HA, focusing on collagen stimulation alongside hydration-related effects.
Although both may be used in professional aesthetic practices for improving skin appearance, they are not interchangeable products. Selection depends on product indications, patient assessment, and practitioner preference.
This comparison is provided for clinical orientation only and does not imply interchangeability.
5. Who can administer Lenisna 200?
Lenisna should only be administered by qualified medical professionals who have appropriate training and experience with injectable aesthetic procedures.
The practitioner is responsible for assessing patient suitability, reviewing contraindications, following the official product instructions, and applying appropriate infection-control procedures.
Patients considering treatment should consult a qualified healthcare professional to determine whether the product is suitable for their individual circumstances.
